Review Article
Pharmacological Modulation of Cardiac Remodeling after Myocardial Infarction
Table 1
Summary of pharmacological therapies against adverse post-MI cardiac remodeling.
| Drug/target | Mechanism of action | Drug application phase | References |
| β-AR blockers | Prevent β-ARs/desensitization | Clinical | [86, 87, 89, 90] | ACE inhibitors | Inhibit angiotensin-converting enzyme | Clinical | [95, 97, 98] | AR blockers | Inhibit angiotensin receptor/desensitization | Clinical | [25, 99, 100] | Anti-inflammatory agents | Resistance to an excessive inflammatory response | Clinical | [106, 107, 110, 115] | Probiotics | Regulate gut microbiota | Preclinical | [126, 127, 130, 131] | Antibiotics | Inhibit matrix metalloproteinase/opening mPTP | Clinical | [132–134, 136] | Circadian rhythm regulators | Control cell fate/modulate oxidant stress | Preclinical | [117, 118, 120] | Noncoding RNAs (ncRNAs) | Reduced the cardiac fibrosis/regulating the autophagy signaling | Preclinical | [121–123, 125] |
|
|